FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Imipenem and Cilastatin for Injection, USP
Status: Discontinuation
»Therapeutic Categories: Anti-Infective; Pediatric

Expand all

Merck Sharp & Dohme Corp. (Revised 05/10/2016)

Company Contact Information:
800-672-6372

Presentation Posting Date Related Information
Primaxin I.V. ADD-Vantage, 250 mg imipenem equivalent and 250 mg cilastatin equivalent and 10 mg sodium bicarbonate as a budder in trays of 25 vals (NDC 0006-3551-58) 01/06/2015 Merck will continue to manufacture and supply other NDCs of PRIMAXIN.
Dear Pharmaceutical Purchaser Letter
Primaxin I.V. ADD-Vantage, 500 mg imipenem equilvalent and 500 mg cilastatin equivalent and 20 mg sodium bicarbonate as a buffer in trays of 25 vials (NDC 0006-3552-59) 01/06/2015 Merck will continue to manufacture and supply other NDCs of PRIMAXIN.
Dear Pharmaceutical Purchaser Letter
Primaxin I.V., 250mg Imipenem equivalent in trays of 25 vials (NDC 0006-3514-58) 05/10/2016 Merck will continue to manufacture and supply other NDCs of PRIMAXIN.
Dear Pharmaceutical Purchaser Letter

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English